Connect with us

Government

Avenir Capital 1Q20 Commentary

Avenir Capital 1Q20 Commentary

Published

on

Avenir Capital commentary for the first quarter ended March 31, 2020, discussing a new addition to their portfolio, Wuliangye Yibin.

Dear Partner:

The Avenir Global Fund (the “Fund”) declined 25.2% for the March 2020 quarter bringing the past 1-year return to -18.1% (net)1. The MSCI ACWI index (AUD) returned -9.7% for the quarter and 3% for the past year.

Get The Full Seth Klarman Series in PDF

Get the entire 10-part series on Seth Klarman in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues.

Q1 2020 hedge fund letters, conferences and more

The last two months have been unlike anything most investors have ever seen. In mid-February, markets were at all-time highs and it was almost impossible for investors to imagine anything that could cloud the horizon. By the middle of March, we were all conducting Zoom calls from our living rooms, as we hid indoors, and watching the same market fall into bear market territory faster than ever before, reaching a trough 35% below the peak2. Value underperformed significantly as investors sought defensive havens, not cyclically exposed or leveraged names. Energy, in particular, was hit hard, with the oil price down 47% in March alone.

Outperformers during the month were Clear Media, Cigna, Wuliangye Yibin and new portfolio entry, Visa. We have written about Clear Media in the past but as we had hoped, the company received a tender offer from a consortium at a 50% premium. We have now exited the stock. Cigna benefitted in part from Biden's presumptive nomination as the Democratic candidate in the US presidential election. Wuliangye Yibin, our Chinese liquor maker outperformed global markets as China began its slow return to normal activity. We added Visa to the portfolio in the month, opportunistically building a position in what we believe is one of the world's great franchises when it fell 40% from recent highs.

The largest detractors to performance in March were ECN Capital, Nexstar Media, Synchrony Financial, Spirit Airlines and General Motors. In the case of ECN, Synchrony and GM, prices fell predominantly due to market concerns that a spike in unemployment would have an impact on consumer spending. Synchrony is a provider of credit to consumers and ECN is essentially a distribution channel for banks and non-bank financials to provide credit to consumers albeit not taking on material credit risk itself. In the case of GM, car purchases are large commitments predominantly made with credit and previous recessions have typically resulted in falling car sales. In the case of Nexstar, it completed an acquisition in late 2019 which has left it relatively levered and as a result indirectly impacted by the temporary seizing up of corporate debt markets, even though in Nexstar's case, the bulk of their debt is not due until 2024 and beyond.

Barron’s magazine recently featured Avenir’s analysis of the company, Live Nation. You can find the Barron’s article here.

Market Commentary

The Covid-19 crisis is a dynamic and rapidly evolving situation. Governments and communities around the world have taken increasingly tough measures in order to control the health emergency, and the likely outcome of these efforts is resulting in the broad-based shutdown of economic activity for a period of unknown duration but, at least, several months.

The full outcome of the economic downturn will be a function of how long the health crisis lasts, until people are able to return to work, and subsequently, how long it takes for demand to return to normal levels. No-one knows for sure if we will see a V-shaped recovery, a U-shaped recovery or, something even worse, such as a long and deep recession or even depression. At this point, following the sharp market rebound from the lows on 23rd March, the market seems to be anticipating a short, sharp Vshaped recovery, although the economic evidence for this is less than clear.

The unprecedented threat to economic activity has seen equity market around the world suffer from some of the steepest falls ever witnessed. Since global markets peaked on February 19th, they have fallen by ~30%, wiping roughly U$23 trillion from the value of global equity markets. The S&P 500 fell 34% to its lows3, in the process, gaining the dubious distinction of being the fastest ever fall of more than 20%. Since the market low, it has bounced back strongly to be only 14% below its all-time highs4. During March, the Dow Jones recorded two of the top five worst one-day performances of all time5. Common volatility measures like the VIX have hit all-time highs, and, in fact, outside of the global financial crises, 5 of the all-time high closes for the VIX occurred in the month of March 2020, so we are witnessing one of the most volatile periods in financial market history6.

The good news is that governments around the world are taking extraordinary measures in order to protect the global economy. The US has promised fiscal stimulus of US$2.4 trillion7 (~11% of GDP)8 to support both small and large businesses along with individuals and may well go higher. European countries are also promising to do “whatever it takes” announcing massive fiscal stimulus programs and support for businesses and individuals affected by the crises. The UK has pledged £350 billion9 of stimulus. In Australia, the figure moves by the day but is equally impressive with the federal government announcing fiscal stimulus of over A$320 billion to date, or 16% of GDP10. These unprecedented measures should help to limit the economic fall out of the crises.

Portfolio Activity

So, what are we at Avenir doing during this crisis? We have taken steps to protect our investors’ capital including reducing our exposure to some of those sectors most directly impacted by the crises including travel related and other more cyclical businesses, and increasing our cash weighting to approximately 15%. We have been working through each company in our portfolio to assess both the near-term impact on our companies and to determine whether they have the liquidity and balance sheet strength to weather the storm and to confirm that our long-term investment cases are intact.

Importantly, we are working to position the portfolio to both protect capital and generate attractive returns for our investors over the next 3-5 years. This can mean proactively trimming more fully valued positions in our portfolio, or those which have been less affected by the share price volatility and adding to those which have been most affected by the market downturn and in which the price-tovalue gap has increased significantly.

The unprecedented volatility has also reduced the price of some high-quality businesses that we don’t currently own and that have been on our Watchlist but have not previously been at valuation levels that have been attractive to us. We will continue to look for opportunities to selectively add high-quality but heavily-discounted names to the portfolio. It is at times of economic and market stress like this that some of the best long-term investment opportunities can be found.

New Addition: Wuliangye Yibin

As some specific examples, we have added Wuliangye Yibin, a Chinese baijiu or alcoholic beverage company, to the portfolio. Wuliangye Yibin has a very attractive competitive position and has delivered earnings growth of over 20% per annum over the past five years. Wuliangye Yibin has many of the characteristics we look for in investments: compelling end market growth in a defensive category, strong market share, high returns on capital and the ability to deploy additional capital at high rates of return, pricing power and a competitive moat created by long standing-consumer brands.

We have also recently added Visa to the portfolio. Visa is a duopoly business that generates tremendous returns on capital and has ample scope to continue to invest capital at high returns. Visa has been a wonderful business for a long time and the near 40% fall in price between 19th February and 23rd March this year gave us the opportunity to add it to the portfolio.

Our largest position in the portfolio currently is Charter, the U.S. broadband business. Charter’s business is very resilient in the current environment where people are working and being schooled from home and the need for data connectivity continues to grow in the modern world. We believe the near term for Charter is well protected and the long term offers tremendous value creation opportunity.

We also have material positions in major health businesses like Cigna and HCA Healthcare which, while potentially affected in the near term, being at the forefront of the health crisis, are world class businesses and we believe they have enormous long-term value.

Outlook

As always, all members of the Avenir investment team are invested in the Fund alongside our investors, and while the current uncertainty and volatility can be very unsettling, we believe that the portfolio is currently trading at deeply discounted levels with the embedded margin of safety and prospective five-year returns as high as they have ever been.

The coronavirus has shut down the economy to an extent not witnessed before and economically sensitive and smaller capitalisation stocks have been severely punished. This covers a very wide range of the economy capturing banks and other financial institutions, energy, travel related companies, hotels, entertainment and restaurant businesses, home builders, auto companies, etc. The fall out has also affected companies previously regarded as infrastructure assets, including airports and toll roads, which have seen revenues approaching zero. Smaller companies have been affected much more than larger companies. The Russell 2000 was down 31% to the end March compared to the S&P 500 which was down 19%11.

Many of the companies most affected by this pandemic are those that were already trading at heavily discounted valuations. At the same time, the market has bid up those companies that will benefit, at least temporarily, from the current crisis, including supermarkets, Netflix, Amazon, etc. Many of these companies had already benefited from 5 years of market conditions that favoured high growth companies with potential high future earnings in a world of low interest rates.

Consequently, the valuation dispersion between the most expensive and the cheapest, which was already high, has now grown even more pronounced. Many of the market leading firms, even after recent falls, are still trading at valuations near, or in excess of, their long-term averages. McDonalds, for example, has fallen 20% from its highs but still trades at a trailing EBIT multiple12 of 20x compared to its average over the past 5-years of 18.3x. In other words, the recent price decline has not made it particularly cheap compared to its own history. We don’t highlight McDonalds, which is a very highquality and resilient company, for any reason other than it is well known.

Apple is another example, which has fallen 17% from its highs (after having fallen as much as 32%, to a recent low of $224, before rebounding) but still trades at 18x EBIT, a 38% premium to its 5-year average of 13x. Much of this multiple expansion occurred during 2019, and we commented in our December 2019 letter that it was difficult to see exactly what had changed during 2019 to justify the market rewarding Apple with an extra $560 billion of market capitalisation and a multiple that is 4-standard deviations greater than its average for the past decade.

There are many similar examples of companies that have fallen by substantial amounts to still sit well above their own long-term trading multiples. This is, of course, due to the elevated level at which markets (the U.S. in particular) were trading at the end of 2019. Prior to the recent abrupt market crash, the Shiller PE was in excess of 30x, a figure only breached twice before in market history, in 1929 and in the 1990-2000 dot.com peak13. Even today14, the Shiller PE sits at 27x compared to its long-term average of 17x. Despite the pandemic we are facing and the near total economic shut down, ongoing geopolitical tension, oil price crashes, the potential for inflation following $7+ trillion of money printing by global central banks, potential decoupling of supply chains, etc, the S&P 500 trades nearly 60% above its long-term average trading multiple.

At the other end of the spectrum is Univar Solutions, one of our portfolio companies. Univar is a chemical distribution business and so is impacted by the level of underlying economic activity. Its share price has been significantly impacted by the coronavirus induced economic slowdown. From its quarter opening price of $24, Univar’s share price declined 74% to its low of $6.40, before rebounding 68% to its quarter-end price of $10.72. At that price, Univar traded at 12x trailing EBIT, a 37% discount to its 5-year average of 19x trailing EBIT. While Univar is, no doubt, somewhat economically sensitive, it is exposed to a range of industries and is largely a consumbles business so revenue is recurring and not subject to dramatic swings like a capital equipment provider.

During the 2008/2009 financial crises, Univar’s rolling twelve month EBITDA declined by only 12.4% from the peak in 4Q2008 to the trough in 4Q2009. Twelve months later (4Q2010) EBITDA had rebounded to its previous high. Univar has market leadership positions in a relatively stable and high return market, limited capital intensity and high free cash flow generation. The company has many suppliers, and even more customers, reducing the potential for unexpected shocks. It is hard to see the chemical distribution industry being disrupted in any meaningful way. Univar also has a high working capital position so, any revenue decline leads to high cash generation as the working capital unwinds, adding to the economic resilience of the business.

In fact, the chemical distribution industry has been a favourite hunting ground of the private equity industry due to its underyling resilience and lack of secular or disruptive threats. Univar, itself, was only returned to the public market in 2015 after a lengthy period in private equity ownership. As of 2013, 5 of the top 7 global chemical distribution businesses were owned by private equity firms highlighting the suitability of these firms for PE ownership. It is quite possible (likely?) that private equity make another play for Univar at some point and that possibility alone should help to provide some kind of a floor under the share price. If Univar were to simply return to its 5-year average multiple, on our view of normalised earnings, we think it possible for the share price to climb to $30 per share or 150% higher than the current price. Univar currently trades at close to a 20% free cash flow yield based on normalised earnings. While the company does carry some debt, it has no major debt maturities until 2024 and its average interest rate is 4.25%, so, we believe it is well placed to weather thes storm and deliver very attractive returns from here.

Regardless of the short-term impact of Covid-19, we believe that the prospects for broad based market returns over the next 5-10 years remain subdued. Over the near term, returns are likely to be determined by investor psychology and behaviour as much as they are by fundamental outcomes. Over the long-term, the fundamental performance of businesses and the price investors pay for those business will win out. Current market stress and volatility, and the wholesale selling of anything with any kind of economic sensitivity, is setting up some extraordinary long-term investment opportunities.

O’Shaughnessy Asset Management (OSAM), a U.S. based quantitative investment firm, calculate that the spread between the earnings yield15 on small cap value and the yield on the U.S. government 10-year bond, which is normally 3-6%, is currently 20%16. Less than 1% of all data observations show a higher earnings yield spread, so the spread is at truly historic proportions. OSAM calculate that in the 10-year period following past observations of such a high spread, small cap value returned 27.9% per year. While the current market dynamics make for a chaotic and, indeed, frustrating period, we believe that it increases the potential for our value-based strategy to outperform the market over the next 5-10 years.

Is Inflation a Thing?

People have long been talking about the central bank ‘experiment’ that has been taking place around the world with the enormous expansion of central bank balance sheets and generational low interest rates. The central bank balance sheet expansion that has occurred post the global financial crisis, however, has been a drop in the bucket compared to the money printing that is being undertaken now as a response to the coronavirus crisis and the unprecedented shutdown of the global economy. Dare we raise the prospect that inflation may rear its head at some point following the extraordinary money printing we are witnessing?

Inflation has also, arguably, been low due to the globalisation that the world has benefited from for the last 30-years. We are now likely to see a reduction in those benefits as companies and countries increasingly ‘decouple’ to avoid being strategically disadvantaged by having supply chains deeply embedded in another country that may turn against them for political reasons. We don’t know the answer, but is it out of the bounds of possibility that inflation and higher interest rates may follow from these factors at some point? If that is the case, then long dated options, like unprofitable but fastgrowing companies, may not be valued in the future the way they are today. These, and many other companies, despite recent falls, still appear priced for perfection, even though we are in the middle of one of the greatest economic shocks we have ever witnessed. Now is a time for operating with a scalpel not a sledgehammer, and we prefer the make-up of our concentrated portfolio to the broader market that appears to be doing its best to ignore the current economic conditions.

Portfolio Positioning

The type of business we favour has not changed and we would still rather buy high quality but appropriately priced businesses than businesses priced for perfection in the current uncertain environment. We are value-oriented investors but we don’t simply buy ‘cheap’ companies. Robust, well-capitalised businesses that can grow underlying value are still, and always will be, our hunting ground. Periods of volatility are also a sweet spot of ours as it allows us to continually improve our margin of safety by reallocating capital from companies with a higher price-to-value ratio to those with a lower price-to-value ratio. By doing so, we aim to substantially reduce risk and increase the prospective returns for the portfolio.

We consider that the Avenir portfolio currently trades at 50%17 of our view of underlying value positioning the portfolio for robust returns over the next 3-5 years. We have not seen such attractive portfolio positioning for many years and investors may consider this as an opportune time to allocate capital to Avenir Capital.

It is important for investors to maintain a long-term view and not have long-term investment goals derailed by short-term events. This is a complex, fast moving and unprecedented situation and we will continue to take thoughtful and measured action to best position the portfolio for the current conditions and to deliver attractive investment returns over the longer-term.

________________________________

Our private equity heritage encourages us to view every investment we make as if we are buying the whole company. This helps to keep our focus on the quality of the underlying business, its long-term prospects and the price we are being asked to pay, rather than trying to speculate as to what the market or individual company prices may do over the short-term.

We believe that our fundamental research-driven and concentrated investment approach will continue to generate attractive investment outcomes for our investors, and the team at Avenir remain
enthusiastic and focused in our search for the next great investment.

“There is nothing more deceptive than an obvious fact.” - Arthur Conan Doyle

Best Regards,

Adrian Warner

Managing Director

The post Avenir Capital 1Q20 Commentary appeared first on ValueWalk.

Read More

Continue Reading

Government

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former…

Published

on

Buried Project Veritas Recording Shows Top Pfizer Scientists Suppressed Concerns Over COVID-19 Boosters, MRNA Tech

Submitted by Liam Cosgrove

Former Project Veritas & O’Keefe Media Group operative and Pfizer formulation analyst scientist Justin Leslie revealed previously unpublished recordings showing Pfizer’s top vaccine researchers discussing major concerns surrounding COVID-19 vaccines. Leslie delivered these recordings to Veritas in late 2021, but they were never published:

Featured in Leslie’s footage is Kanwal Gill, a principal scientist at Pfizer. Gill was weary of MRNA technology given its long research history yet lack of approved commercial products. She called the vaccines “sneaky,” suggesting latent side effects could emerge in time.

Gill goes on to illustrate how the vaccine formulation process was dramatically rushed under the FDA’s Emergency Use Authorization and adds that profit incentives likely played a role:

"It’s going to affect my heart, and I’m going to die. And nobody’s talking about that."

Leslie recorded another colleague, Pfizer’s pharmaceutical formulation scientist Ramin Darvari, who raised the since-validated concern that repeat booster intake could damage the cardiovascular system:

None of these claims will be shocking to hear in 2024, but it is telling that high-level Pfizer researchers were discussing these topics in private while the company assured the public of “no serious safety concerns” upon the jab’s release:

Vaccine for Children is a Different Formulation

Leslie sent me a little-known FDA-Pfizer conference — a 7-hour Zoom meeting published in tandem with the approval of the vaccine for 5 – 11 year-olds — during which Pfizer’s vice presidents of vaccine research and development, Nicholas Warne and William Gruber, discussed a last-minute change to the vaccine’s “buffer” — from “PBS” to “Tris” — to improve its shelf life. For about 30 seconds of these 7 hours, Gruber acknowledged that the new formula was NOT the one used in clinical trials (emphasis mine):


“The studies were done using the same volume… but contained the PBS buffer. We obviously had extensive consultations with the FDA and it was determined that the clinical studies were not required because, again, the LNP and the MRNA are the same and the behavior — in terms of reactogenicity and efficacy — are expected to be the same.

According to Leslie, the tweaked “buffer” dramatically changed the temperature needed for storage: “Before they changed this last step of the formulation, the formula was to be kept at -80 degrees Celsius. After they changed the last step, we kept them at 2 to 8 degrees celsius,” Leslie told me.

The claims are backed up in the referenced video presentation:

I’m no vaccinologist but an 80-degree temperature delta — and a 5x shelf-life in a warmer climate — seems like a significant change that might warrant clinical trials before commercial release.

Despite this information technically being public, there has been virtually no media scrutiny or even coverage — and in fact, most were told the vaccine for children was the same formula but just a smaller dose — which is perhaps due to a combination of the information being buried within a 7-hour jargon-filled presentation and our media being totally dysfunctional.

Bohemian Grove?

Leslie’s 2-hour long documentary on his experience at both Pfizer and O’Keefe’s companies concludes on an interesting note: James O’Keefe attended an outing at the Bohemian Grove.

Leslie offers this photo of James’ Bohemian Grove “GATE” slip as evidence, left on his work desk atop a copy of his book, “American Muckraker”:

My thoughts on the Bohemian Grove: my good friend’s dad was its general manager for several decades. From what I have gathered through that connection, the Bohemian Grove is not some version of the Illuminati, at least not in the institutional sense.

Do powerful elites hangout there? Absolutely. Do they discuss their plans for the world while hanging out there? I’m sure it has happened. Do they have a weird ritual with a giant owl? Yep, Alex Jones showed that to the world.

My perspective is based on conversations with my friend and my belief that his father is not lying to him. I could be wrong and am open to evidence — like if boxer Ryan Garcia decides to produce evidence regarding his rape claims — and I do find it a bit strange the club would invite O’Keefe who is notorious for covertly filming, but Occam’s razor would lead me to believe the club is — as it was under my friend’s dad — run by boomer conservatives the extent of whose politics include disliking wokeness, immigration, and Biden (common subjects of O’Keefe’s work).

Therefore, I don’t find O’Keefe’s visit to the club indicative that he is some sort of Operation Mockingbird asset as Leslie tries to depict (however Mockingbird is a 100% legitimate conspiracy). I have also met James several times and even came close to joining OMG. While I disagreed with James on the significance of many of his stories — finding some to be overhyped and showy — I never doubted his conviction in them.

As for why Leslie’s story was squashed… all my sources told me it was to avoid jail time for Veritas executives.

Feel free to watch Leslie’s full documentary here and decide for yourself.

Fun fact — Justin Leslie was also the operative behind this mega-viral Project Veritas story where Pfizer’s director of R&D claimed the company was privately mutating COVID-19 behind closed doors:

Tyler Durden Tue, 03/12/2024 - 13:40

Read More

Continue Reading

International

Association of prenatal vitamins and metals with epigenetic aging at birth and in childhood

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging…

Published

on

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

Credit: 2024 Bozack et al.

“[…] our findings support the hypothesis that the intrauterine environment, particularly essential and non-essential metals, affect epigenetic aging biomarkers across the life course.”

BUFFALO, NY- March 12, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as “Aging (Albany NY)” and “Aging-US” by Web of Science) Volume 16, Issue 4, entitled, “Associations of prenatal one-carbon metabolism nutrients and metals with epigenetic aging biomarkers at birth and in childhood in a US cohort.”

Epigenetic gestational age acceleration (EGAA) at birth and epigenetic age acceleration (EAA) in childhood may be biomarkers of the intrauterine environment. In this new study, researchers Anne K. Bozack, Sheryl L. Rifas-Shiman, Andrea A. Baccarelli, Robert O. Wright, Diane R. Gold, Emily Oken, Marie-France Hivert, and Andres Cardenas from Stanford University School of Medicine, Harvard Medical School, Harvard T.H. Chan School of Public Health, Columbia University, and Icahn School of Medicine at Mount Sinai investigated the extent to which first-trimester folate, B12, 5 essential and 7 non-essential metals in maternal circulation are associated with EGAA and EAA in early life. 

“[…] we hypothesized that OCM [one-carbon metabolism] nutrients and essential metals would be positively associated with EGAA and non-essential metals would be negatively associated with EGAA. We also investigated nonlinear associations and associations with mixtures of micronutrients and metals.”

Bohlin EGAA and Horvath pan-tissue and skin and blood EAA were calculated using DNA methylation measured in cord blood (N=351) and mid-childhood blood (N=326; median age = 7.7 years) in the Project Viva pre-birth cohort. A one standard deviation increase in individual essential metals (copper, manganese, and zinc) was associated with 0.94-1.2 weeks lower Horvath EAA at birth, and patterns of exposures identified by exploratory factor analysis suggested that a common source of essential metals was associated with Horvath EAA. The researchers also observed evidence of nonlinear associations of zinc with Bohlin EGAA, magnesium and lead with Horvath EAA, and cesium with skin and blood EAA at birth. Overall, associations at birth did not persist in mid-childhood; however, arsenic was associated with greater EAA at birth and in childhood. 

“Prenatal metals, including essential metals and arsenic, are associated with epigenetic aging in early life, which might be associated with future health.”

 

Read the full paper: DOI: https://doi.org/10.18632/aging.205602 

Corresponding Author: Andres Cardenas

Corresponding Email: andres.cardenas@stanford.edu 

Keywords: epigenetic age acceleration, metals, folate, B12, prenatal exposures

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Launched in 2009, Aging publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways.

Please visit our website at www.Aging-US.com​​ and connect with us:

  • Facebook
  • X, formerly Twitter
  • Instagram
  • YouTube
  • LinkedIn
  • Reddit
  • Pinterest
  • Spotify, and available wherever you listen to podcasts

 

Click here to subscribe to Aging publication updates.

For media inquiries, please contact media@impactjournals.com.

 

Aging (Aging-US) Journal Office

6666 E. Quaker Str., Suite 1B

Orchard Park, NY 14127

Phone: 1-800-922-0957, option 1

###


Read More

Continue Reading

International

A beginner’s guide to the taxes you’ll hear about this election season

Everything you need to know about income tax, national insurance and more.

Cast Of Thousands/Shutterstock

National insurance, income tax, VAT, capital gains tax, inheritance tax… it’s easy to get confused about the many different ways we contribute to the cost of running the country. The budget announcement is the key time each year when the government shares its financial plans with us all, and announces changes that may make a tangible difference to what you pay.

But you’ll likely be hearing a lot more about taxes in the coming months – promises to cut or raise them are an easy win (or lose) for politicians in an election year. We may even get at least one “mini-budget”.

If you’ve recently entered the workforce or the housing market, you may still be wrapping your mind around all of these terms. Here is what you need to know about the different types of taxes and how they affect you.

The UK broadly uses three ways to collect tax:

1. When you earn money

If you are an employee or own a business, taxes are deducted from your salary or profits you make. For most people, this happens in two ways: income tax, and national insurance contributions (or NICs).

If you are self-employed, you will have to pay your taxes via an annual tax return assessment. You might also have to pay taxes this way for interest you earn on savings, dividends (distribution of profits from a company or shares you own) received and most other forms of income not taxed before you get it.

Around two-thirds of taxes collected come from people’s or business’ incomes in the UK.

2. When you spend money

VAT and excise duties are taxes on most goods and services you buy, with some exceptions like books and children’s clothing. About 20% of the total tax collected is VAT.

3. Taxes on wealth and assets

These are mainly taxes on the money you earn if you sell assets (like property or stocks) for more than you bought them for, or when you pass on assets in an inheritance. In the latter case in the UK, the recipient doesn’t pay this, it is the estate paying it out that must cover this if due. These taxes contribute only about 3% to the total tax collected.

You also likely have to pay council tax, which is set by the council you live in based on the value of your house or flat. It is paid by the user of the property, no matter if you own or rent. If you are a full-time student or on some apprenticeship schemes, you may get a deduction or not have to pay council tax at all.


Quarter life, a series by The Conversation

This article is part of Quarter Life, a series about issues affecting those of us in our 20s and 30s. From the challenges of beginning a career and taking care of our mental health, to the excitement of starting a family, adopting a pet or just making friends as an adult. The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.

You may be interested in:

If you get your financial advice on social media, watch out for misinformation

Future graduates will pay more in student loan repayments – and the poorest will be worst affected

Selling on Vinted, Etsy or eBay? Here’s what you need to know about paying tax


Put together, these totalled almost £790 billion in 2022-23, which the government spends on public services such as the NHS, schools and social care. The government collects taxes from all sources and sets its spending plans accordingly, borrowing to make up any difference between the two.

Income tax

The amount of income tax you pay is determined by where your income sits in a series of “bands” set by the government. Almost everyone is entitled to a “personal allowance”, currently £12,570, which you can earn without needing to pay any income tax.

You then pay 20% in tax on each pound of income you earn (across all sources) from £12,570-£50,270. You pay 40% on each extra pound up to £125,140 and 45% over this. If you earn more than £100,000, the personal allowance (amount of untaxed income) starts to decrease.

If you are self-employed, the same rates apply to you. You just don’t have an employer to take this off your salary each month. Instead, you have to make sure you have enough money at the end of the year to pay this directly to the government.


Read more: Taxes aren't just about money – they shape how we think about each other


The government can increase the threshold limits to adjust for inflation. This tries to ensure any wage rise you get in response to higher prices doesn’t lead to you having to pay a higher tax rate. However, the government announced in 2021 that they would freeze these thresholds until 2026 (extended now to 2028), arguing that it would help repay the costs of the pandemic.

Given wages are now rising for many to help with the cost of living crisis, this means many people will pay more income tax this coming year than they did before. This is sometimes referred to as “fiscal drag” – where lower earners are “dragged” into paying higher tax rates, or being taxed on more of their income.

National insurance

National insurance contributions (NICs) are a second “tax” you pay on your income – or to be precise, on your earned income (your salary). You don’t pay this on some forms of income, including savings or dividends, and you also don’t pay it once you reach state retirement age (currently 66).

While Jeremy Hunt, the current chancellor of the exchequer, didn’t adjust income tax meaningfully in this year’s budget, he did announce a cut to NICs. This was a surprise to many, as we had already seen rates fall from 12% to 10% on incomes higher than £242/week in January. It will now fall again to 8% from April.


Read more: Budget 2024: experts explain what it means for taxpayers, businesses, borrowers and the NHS


While this is charged separately to income tax, in reality it all just goes into one pot with other taxes. Some, including the chancellor, say it is time to merge these two deductions and make this simpler for everyone. In his budget speech this year, Hunt said he’d like to see this tax go entirely. He thinks this isn’t fair on those who have to pay it, as it is only charged on some forms of income and on some workers.

I wouldn’t hold my breath for this to happen however, and even if it did, there are huge sums linked to NICs (nearly £180bn last year) so it would almost certainly have to be collected from elsewhere (such as via an increase in income taxes, or a lot more borrowing) to make sure the government could still balance its books.

A young black man sits at a home office desk with his feet up, looking at a mobile phone
Do you know how much tax you pay? Alex from the Rock/Shutterstock

Other taxes

There are likely to be further tweaks to the UK’s tax system soon, perhaps by the current government before the election – and almost certainly if there is a change of government.

Wealth taxes may be in line for a change. In the budget, the chancellor reduced capital gains taxes on sales of assets such as second properties (from 28% to 24%). These types of taxes provide only a limited amount of money to the government, as quite high thresholds apply for inheritance tax (up to £1 million if you are passing on a family home).

There are calls from many quarters though to look again at these types of taxes. Wealth inequality (the differences between total wealth held by the richest compared to the poorest) in the UK is very high (much higher than income inequality) and rising.

But how to do this effectively is a matter of much debate. A recent study suggested a one-off tax on total wealth held over a certain threshold might work. But wealth taxes are challenging to make work in practice, and both main political parties have already said this isn’t an option they are considering currently.

Andy Lymer and his colleagues at the Centre for Personal Financial Wellbeing at Aston University currently or have recently received funding for their research work from a variety of funding bodies including the UK's Money and Pension Service, the Aviva Foundation, Fair4All Finance, NEST Insight, the Gambling Commission, Vivid Housing and the ESRC, amongst others.

Read More

Continue Reading

Trending